NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) is a biotech company focused on developing novel peptide based drugs, called Emtins, which have the potential to treat neurodegenerative conditions. Emtin peptides are modelled on the active sites of a protein expressed in the brain following brain injury. NSB’s lead peptide candidate, EmtinB, is most advanced as a treatment for Alzheimer’s disease. EmtinB has been shown to induce the survival and regrowth of neurons through binding to specific receptors expressed by neuronal cells. The peptide offers a novel therapeutic treatment pathway for neurodegenerative diseases that are currently without effective treatment options, such as Alzheimer’s disease.
Mr Brian Leedman – Chairman
Brian Leedman is the Non-executive Chairman and as a biotechnology entrepreneur has co-founded four ASX listed healthcare companies. He is formerly the Chairman of Ausbiotech (WA), the Industry Association of Biotechnology Companies in Australia and holds a BEc and MBA from UWA.
What is your rationale for attending 121 Tech Investment?
What recent news would you like to highlight to investors attending?
Commencing human trials for Alzheimer’s and back of the eye diseases
What are your key goals for the next 3, 6 and 12 months?
Commence human studies
Strong recruitment at hospital sites in Australia
Positive results leading to further studies/licencing/partnerships
What do you see as the key risks and challenges facing your company at the moment and how are you overcoming these?
Positive results from Phase I clinical study
In a sentence, what do you think makes your company such a compelling investment?
Our approach to the treatment of Alzheimer’s disease focuses on neurological cell death prevention/rejuvenation rather than Beta-Amyloid plaque removal